Anemia and chemotherapy;Anémie et chimiothérapie

Bulletin du Cancer

Volumn 90, Issue 4 SPEC. ISS., 2003, Pages

  Ray Coquard, Isabelle ^a   Bachelot, Thomas ^a   Sebban, Catherine ^a   Biron, Pierre ^a   Guastalla, Jean Paul ^a   Blay, Jean Yves ^b  

^a CENTRE LÉON BÉRARD   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

And erythropoietin; Anemia; Blood transfusions; Cancer; Chemotherapy; Toxicity

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HEMOGLOBIN; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL; PREDNISONE; PROCARBAZINE; RECOMBINANT ERYTHROPOIETIN; TOPOTECAN; VINCRISTINE; VINCRISTINE SULFATE;

ANEMIA; BLOOD TRANSFUSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HEMATOCRIT; HEMOLYTIC UREMIC SYNDROME; HUMAN; MALE; NEPHROTOXICITY; NUTRITION; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SOCIAL ASPECT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

AGE FACTORS; ANEMIA; ANTINEOPLASTIC AGENTS; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; MALE; NEOPLASMS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 0037833478     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Spivak JL. Recombinant human erythropoietin and the anemia of cancer. Blood 1994 ; 84 : 997-1004.
2. Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 1994 ; 73 : 2535-42.
3. Zucker S. Anemia in cancer. Cancer Invest 1985 ; 3 : 249-60.
4. Means RT, Krantz SB. Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoletin. Blood 1991 ; 78 : 2564-7.
5. Zanjani ED, McGlave PB, Davies SF, Banisadre M, Kaplan ME, Sarosi GA. In vitro suppression of erythropoiesis by bone marrow adherent cells from some patients with fungal infection. Br J Haematol 1982 ; 50 : 479-90.
6. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992 ; 79 : 1987-94.
7. Teppo AM, Maury CP. Radioimmunoassay of tumor necrosis factor in serum. Clin Chem 1987 ; 33 : 2024-7.
8. Dainiak N, Kulkarni V, Howard D, Kalmanti M, Dewey MC, Hoffman R. Mechanisms of abnormal erythropoiesis in malignancy. Cancer 1983 ; 51 : 1101-6.
9. Guardiola E, Pivot X, Tchicknavorian X, Magne N, Otto J, Thyss A, et al. Combination of cisplatin-doxorubicin-cyclophosphamide in adenocarcinoma of unknown primary site: a phase II trial. Am J Clin Oncol 2001 ; 24 : 372-5.
10. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999 ; 91 : 1616-34.
11. Irvine D, Vincent L, Graydon JE, Bubela N, Thompson L. The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy: a comparison with the fatigue experienced by healthy individuals. Cancer Nurs 1994 ; 17 : 367-78.
12. Asco. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994 ; 12 : 2471-508.
13. Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999 ; 17 : 3333-55.
14. Brenner DE, Wiernik PH, Wesley M, Bachur NR. Acute doxorubicin toxicity: relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia. Cancer 1984 ; 53 : 1042-8.
15. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990 ; 322 : 1689-92.
16. Canetta R, Franks C, Smaldone L, Bragman K, Rozencweig M. Clinical status of carboplatin. Ontology (Huntingt) 1987 ; 1 : 61-70.
17. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, et al. Phase II study of taxol in patients with untreated advanced non-small- cell lung cancer. J Natl Cancer Inst 1993 ; 85 : 384-8.
18. Francis P, Schneider J, Hann L, Balmaceda C, Barakat R, Phillips M, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994 ; 12 : 2301-8.
19. Vokes EE, Rosenberg RK, Jahanzeb M, Craig JB, Gralla RJ, Belani CP, et al. Multicenter phase II study of weekly oral vinorelbine for stage IV non- small-cell lung cancer. J Clin Oncol 1995 ; 13 : 637-44.
20. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1994 ; 12 : 1821-6.
21. Hunter DJ, McKee CM, Sanderson CF, Black NA. Appropriate indications for prostatectomy in the UK-results of a consensus panel. J Epidemiol Community Health 1994 ; 48 : 58-64.
22. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997 ; 15 : 251-60.
23. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French inrergroup study. J Clin. Oncol 1997 ; 15 : 808-15.
24. ten Bokkel HW, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997 ; 15 : 2183-93.
25. Dorval T, Soussain C, Beuzeboc P, Garcia-Giralt E, Jouve M, Livartowski A, et al. Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer. J Infus Chemother 1996 ; 6 : 47-9.
26. Tartour E, Blay JY, Dorval T, Escudier B, Mosseri V, Douillard JY, et al. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol 1996 ; 14 : 1697-703.
27. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998 ; 16 : 405-10.
28. Petrelli N, Douglass HO Jr., Herrera L, Russell D, Stablein DM, Bruckner HW, et al. The modulation of fluorouracil with leucovorin in metastatic colorecral carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989 ; 7 : 1419-26.
29. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus merhotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Ontology Group study. J Clin Oncol 1992 ; 10 : 1245-51.
30. Pirker R, Krajnik G, Zochbauer S, Malayeri R, Kneussl M, Huber H. Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC). Ann Oncol 1995 ; 6 : 833-5.
31. 2) plus carboplatin in non-small cell lung cancer: a randomized study. Semin Oncol 1997 ; 24 : S12.
32. Wozniak AJ, Samson MK, Crawford ED, Ford CD, Altman SJ, Stephens RL, et al. A randomized trial of cisplatin, vinblastine and bleomycin versus vinblastine, cisplatin and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study. J Clin Oncol 1991 ; 9 : 70-6.
33. Miller AA, Niell HB, Griffin JP. Phase II study of prolonged oral etoposide in combination with intravenous cisplatin in advanced non-small cell lung cancer. Lung Cancer 1995 ; 12 : 59-65.
34. Luikart SD, Goutsou M, Mitchell ED, Van Echo DA, Modeas CR, Propert KJ. et al. Phase I/II trial etoposide and carboplatin in extensive small-cell lung cancer. A report from the Cancer and Leukemia Group B. Am J Clin Oncol. 1993 ; 16 : 127-31.
35. Wolff AC, Ettinger DS, Neuberg D, Comis RL, Ruckdeschel JC, Bonomi PD, et al. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1995 ; 13 : 1615-22.
36. Aisner J, Cirrincione C, Perloff M, Perry M, Budman D, Abrams J, et al. Combination chemotherapy for metastatic or recurrent carcinoma of the breast - a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281. J Clin Oncol 1995 ; 13 : 1443-52.
37. Nabholtz JM, Mackey J, Smylie M, Tonkin K. Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer. Semin Oncol 1998 ; 25 : 27-31.
38. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996 ; 334 : 1-6.
39. Conte PF, Bruzzone M, Chiara S, Sertoli MR, Daga MG, Rubagotti A, et al. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. J Clin Oncol 1986 ; 4 : 965-71.
40. Meyer RM, Browman GP, Samosh ML, Benger AM, Bryant-Lukosius D, Wilson WE, et al. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 1995 ; 13 : 2386-93.
41. Bokemeyer C, Harstrick A, Ruther U, Metzner B, Arseniev L, Kadar J, et al. Sequential treatment with high-dose VIP-chemotherapy plus peripheral blood stem cell support in advanced germ cell cancer (abstr.). Proc Am Assoc Cancer Res 1995 ; 14 : 230.
42. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992 ; 327 : 1478-84.
43. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992 ; 10 : 257-63.
44. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000 ; 355 : 1041-7.
45. Crino L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1997 ; 15 : 297-303.
46. Gordon LI, Harrington D, Andersen J, Colgan J, Glick J, Neiman R, et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992 ; 327 : 1342-9.
47. Revicki DA, Brown RE, Henry, DH, McNeill MV, Rios A, Watson T. Recombinant human eryrhropoietin and health-related quality of life of AIDS patients with anemia. J Acquir Immune Defic Syndr 1994 ; 7 : 474-84.
48. Miller CB, Platanias LC, Mills SR, Zahurak ML, Ratain MJ, Ettinger DS, et al. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst 1992 ; 84 : 98-103.
49. Pivot X, Guardiola E, Etienne M, Thyss A, Foa C, Otto J, et al. An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemia. Eur J Cancer 2000 ; 36 : 852-7.
50. Abels RI. Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol 1992 ; 87 (suppl. 1) : 4-11.
51. Doll DC, Weiss RB. Hemolytic anemia associated with antineoplastic agents. Cancer Treat Rep 1985 ; 69 : 777-82.
52. Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozencweig M, Young RC, et al. Toxic effects of cis-dichlorodiammineplatinum (II) in man. Cancer Treat Rep 1979 ; 63 : 1527-31.
53. Getaz EP, Beckley S, Fitzpatrick J, Dozier A. Cisplatin-induced hemolysis. N Engl J Med 1980 ; 302 : 334-5.
54. Milano G, Caldani C, Khater R, Launay JM, Soummer AM, Namer M, et al. Time- and dose-dependent inhibition of erythrocyte glutathione peroxidase by cisplatin. Biochem Pharmacol 1988 ; 37 : 981-2.
55. Smith DH, Goldwasser E, Vokes EE. Serum immunoerythropoietin levels in patients with cancer receiving cisplatin-based chemotherapy. Cancer 1991 ; 68 : 1101-5.
56. Bray GL, Reaman GH. Erythropoietin deficiency : a complication of cisplatin therapy and its treatment with recombinant human erythropoietin. Am J Pediatr Hematol Oncol 1991 ; 13 : 426-30.
57. Canetta R, Rozencweig M, Carter SKI. Carboplatin: the clinical spectrum to date. Cancer Treat Rev 1985 ; 12 : 125-36.
58. Gasparini G, Recher G, Testolin A, Dal Fior S, Panizzoni GA, Cristoferi V, et al. Synchronous radiotherapy and chemotherapy with cisplatin in the management of locally advanced or recurrent head and neck cancer. Am J Clin Oncol 1992 ; 15 : 242-9.
59. Arnold R, Schmeiser T, Heit W, Frickhofen N, Pabst G, Heimpel H, et al. Hematopoietic reconstitution after bone marrow transplantation. Exp Hematol 1986 ; 14 : 271-7.
60. Miller CB. Erythropoietin. In : Armitage JO, Antman K. High dose cancer therapy. 3 ed. Philadelphia: Lippincott Williams and Wilkins, 2000 : 437-54.
61. Rouesse J, Spielmann M, Turpin F, Le Chevalier T, Azab M, Mondesir JM. Phase II study of elliptinium acetate salvage treatment of advanced breast cancer. Eur J Cancer 1993 ; 29A : 856-9.
62. Verweij J, Pinedo HM. Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs 1990 ; 1 : 5-13.
63. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994 ; 12 : 29-34.
64. Spaeth D, Marchal C, Blanc-Vincent MP. Standards, Options, and Recommendations for using erythropoietin in cancerology. Bull Cancer 1998 ; 85 : 337-46.
65. Spaeth D, Marchal C, Bataillard A, Blanc-Vincent MP. Updating 1999 of Standards, Options and Recommendations (SOR) for the clinical use of erythropoietin in oncology. Fédération of The french cancer centres (FNCLCC). Bull Cancer 1999 ; 86 : 631-9.
66. Horsman MR, Overgaard J. Overcoming tumour radiation resistance resulting from acute hypoxia. Eur J Cancer 1992 ; 28A : 717-8.
67. Dische S. Hypoxia and local tumour control. Part 2. Radiother Oncol 1991 ; 20 (suppl. 1) : 9-11.
68. Overgaard J, Hansen HS, Jorgensen K, Hjelm HM. Primary radiotherapy of larynx and pharynx carcinoma: an analysis of some factors influencing local control and survival. Int J Radiat Oncol Biol Phys 1986 ; 12 : 515-21.
69. Schreiner P, Siracka E, Siracky J, Manka I. The effect of anemia on the radiotherapy results of the uterine cervix cancer. Neoplasma 1975 ; 22 : 655-60.
70. Hirst DG. Anemia: a problem or an opportunity in radiotherapy? Int J Radiat Oncol Biol Phys 1986 ; 12 : 2009-17.
71. Rustowski J, Kupsc W. Factors influencing the results of radiotherapy in cases of inoperable endometrial cancer. Gynecol Oncol 1982 ; 14 : 185-93.
72. Bush RS, Jenkin RD, Allt WE, Beale FA, Bean H, Dembo AJ, et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer Suppl 1978 ; 37 : 302-6.
73. Perry MC. Appendix-WHO toxicity guidelines. In : Perry MC. The Chemotherapy Sources Book. 1 ed. Baltimore: Williams & Wilkins Inc., 1992 : 1132-44.
74. Skillings JR, Sridhar FG, Wong C, Paddock L. The frequency of red cell transfusion for anemia in patients receiving chemotherapy: a retrospective cohort study. Am J Clin Oncol 1993 ; 16 : 22-5.
75. Ray-Coquard I, Le Cesne A, Rubio MT, Mermet J, Maugard C, Ravaud A, et al. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. J Clin Oncol 1999 ; 17 : 2840-.
76. Genetet B, Andreu G, Bidet J. Aide-mémoire de transfusion sanguine. Paris: Flammarion, 1991.
77. Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 1996 ; 14 : 636-43.
78. Blay JY, Le Cesne A, Mermet C, Maugard C, Ravaud A, Chevreau C, et al. A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood 1998 ; 92 : 405-10.
79. Ray-Coquatd I, Blay JY, Sebban C, Bachelor T, Biron P. Lymphopenia ≤ 700/LI and performans status > 1 as prognostic factors of early death after conventional cytotoxic chemotherapy. 18, 576. 1999. 35th annual meeting of American Society of Clinical Oncology, Atlanta GA.
80. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity response, and survival analysis. J Clin Oncol 1995 ; 13 : 1860-70.
81. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997 ; 15 : 1218-34.
82. Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 1997 ; 15 : 2715-21.
83. Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 1998 ; 78 : 781-7.
84. Toy PT, Menozzi D, Strauss RG, Stehling LC, Kruskall M, Ahn DK. Efficacy of preoperative donation of blood for autologous use in radical prostatectomy. Transfusion 1993 ; 33 : 721-4.
85. Hillyer CD, Tiegerman KO, Berkman EM. Evaluation of the red cell storage lesion after irradiation in filtered packed red cell units. Transfusion 1991 ; 31 : 497-9.
86. Tartter PI, Quintero S, Barron DM. Perioperative blood transfusion associated with infectious complications after colorectal cancer operations. Am J Surg 1986 ; 152 : 479-82.
87. Burrows L, Tarrier P. Effect of blood transfusions on colonic malignancy recurrent rate. Lancet 1982 ; 2 : 662.
88. Beck MN, Beck D. Recombinant erythropoietin in acute chemotherapy-induced anemia of children with cancer. Med Pediatr Oncol 1995 ; 25 : 17-21.
89. Bolonaki I, Stiakaki E, Lydaki E, Dimitriou H, Kambourakis A, Kalmantis T, et al. Treatment with recombinant human erythropoietin in children with malignancies. Pediatr Hematol Oncol 1996 ; 13 : 111-21.
90. Tsukuda M, Mochimatsu I, Nagahara T, Kokatsu T, Sawaki S, Kubota A, et al. Clinical application of recombinant human erythropoietin for treatments in patients with head and neck cancer. Cancer Immunol Immunother 1993 ; 36 : 52-6.
91. Markman M, Reichman B, Hakes T, Rubin S, Jones W, Lewis JL, et al. The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. Gynecol Oncol 1993 ; 49 : 172-6.
92. Cascinu S, Del Ferro E, Fedeli A, Ligi M, Alessandroni P, Catalano G. Recombinant human erythtopoietin treatment in elderly cancer patients with cisplatin-associated anemia. Oncology 1995 ; 52 : 422-6.
93. Ludwig H, Sundal E, Pecherstorfer M, Leitgeb C, Bauernhofer T, Beinhauer A, et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 1995 ; 76 : 2319-29.
94. Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994 ; 84 : 1056-63.
95. Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995 ; 86 : 4446-53.
96. Cascinu S, Fedeli A, Del Ferro E, Luzi FS, Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated anemia : a randomized, double-blind trial with placebo. J Clin Oncol 1994 ; 12 : 1058-62.
97. Gamucci T, Thorel MF, Frasca AM, Giannarell D, Calabresi F. Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatin. Eur J Cancer 1993 ; 29A (suppl. 2) : S13-14.
98. Case DC, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993 ; 85 : 801-6.
99. de Campos E, Radford J, Steward W, Milroy R, Dougal M, Swindell R, et al. Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J Clin Oncol 1995 ; 13 : 1623-31.
100. Wurnig C, Windhager R, Schwameis E, Kotz R, Zoubek A, Stockenhuber F, et al. Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). Transfusion 1996 ; 36 : 155-9.
101. Crawford J, Blackwell S. Erythropoietin and the management of anemia in patients with lung cancer. Cancer Control 1998 ; 5 : 26-32.
102. Bokkel Huinink WW, de Swart CA, van Tootn DW, Morack G, Breed WP, Hillen HF, et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 1998 ; 15 : 174-82.
103. Welch RS, James RD, Wilkinson PM, FB. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer. Cancer J Sci Am 1995 ; 1 : 261.
104. Thatcher N. Management of chemotherapy-induced anemia in solid tumors. Semin Oncol 1998 ; 25 : 23-6.
105. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998 ; 16 : 3412-25.
106. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy : results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001 ; 19 : 2865-74.
107. Chao NJ, Schriber JR, Long GD, Negrin RS, Catolico M, Brown BW, et al. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood 1994 ; 83 : 2823-8.
108. Link H, Boogaerts MA, Fauser AA, Slavin S, Reiffers J, Gorin NC, et al. A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 1994 ; 84 : 3327-35.
109. Berdel WE, Oberberg D, Reufi B, Thiel E. Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. Ann Hematol 1991 ; 63 : 5-8.
110. Bauer E, Danhauser-Riedl S, De Riese W, Raab HR, Sandner S, Meyer HJ, et al. Effects of recombinant human erythropoietin on clonogenic growth of primary human tumour specimens in vitro. Eur J Cancer 1992 ; 28A : 1769.
111. Eschbach JW, Aquiling T, Haley NR, Fan MH, Blagg CR. The long-term effects of recombinant human erythropoietin on the cardiovascular system. Clin Nephrol 1992 ; 38 (suppl. 1) : S98-103.